Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CT-001
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CT-001 is an engineered FVIIa that is designed to address the limitations of the recombinant FVIIa, approved for use in Hemophilia A and B patients with inhibitors, congenital FVII deficiency and Glanzmann’s thrombasthenia with refractoriness to platel...
Brand Name : CT-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 27, 2023
Lead Product(s) : CT-001
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CT-001
Therapeutic Area : Hematology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CT-001 is an engineered version of FVIIa that is designed to address the limitations of the recombinant FVIIa, approved for use in Hemophilia A and B patients with inhibitors, congenital FVII deficiency.
Brand Name : CT-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 16, 2022
Lead Product(s) : CT-001
Therapeutic Area : Hematology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CT-001
Therapeutic Area : Hematology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CT-001 is an engineered version of clotting factor FVIIa designed to address safety and efficacy limitations of recombinant FVIIa is approved for use in Hemophilia A and B patients with inhibitors.
Brand Name : CT-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 12, 2022
Lead Product(s) : CT-001
Therapeutic Area : Hematology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CT-001
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The in vivo studies compared the safety and efficacy of CT-001 versus recombinant FVIIa in multiple mouse models. The studies confirmed that desialylation of the molecule increased the speed by which it cleared from the body.
Brand Name : CT-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 07, 2022
Lead Product(s) : CT-001
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?